FDA Brief

Warning letters Biologics

FDA warning letter to

Genetrace

High riskIssued Jan 8Posted Jan 20Center for Biologics Evaluation and Research (CBER)

FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.

What happened

FDA reviewed Genetrace’s website in January 2026 and found it offered an HIV serological diagnostic dried blood spot card self-collection kit for delivery to individuals to collect samples at home and ship them to laboratories for HIV testing. FDA said the kit has no approved premarket approval application (PMA) or approved investigational device exemption (IDE), and no required premarket notification (510(k)) was provided. FDA had previously written the firm on March 31, 2025 about offering such kits.

What FDA found

  1. FDA says the kit is adulterated because it lacks an approved premarket approval application (PMA) or an approved investigational device exemption (IDE).

    FD&C Act section 501(f)(1)(B), 21 U.S.C. 351(f)(1)(B); sections 515(a) and 520(g), 21 U.S.C. 360e(a), 360j(g)
  2. FDA says the kit is misbranded because Genetrace did not give FDA the required premarket notification before commercial distribution.

    FD&C Act section 502(o), 21 U.S.C. 352(o); section 510(k), 21 U.S.C. 360(k)
  3. FDA says the kit has not been authorized for any use, including HIV serological diagnostic testing.

  4. FDA says Genetrace has not submitted any premarket submission to FDA seeking authorization to market this kit.

What FDA wants

FDA asks Genetrace to immediately stop any activity that makes the HIV DBS self-collection kit misbranded or adulterated. Within 15 working days of receiving the letter, Genetrace must write to FDA with the steps taken, an explanation of how recurrence will be prevented, and supporting documents; if not complete, it must give the reason and a completion date.

Who should pay attention

  • companies selling at-home diagnostic collection kits
  • labs that receive self-collected samples for HIV testing
  • distributors or brands offering HIV self-tests

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk